(OAKVILLE, Ontario) July 13, 2022 – Very pleased and proud to announce that our ForYOU Patient Support Program is up and actively supporting Canadian patients. Officially launched and enrolling patients in need as of July 4, with the first dispense of XPOVIO in...

(OAKVILLE, Ontario) le 7 juin 2022 – FORUS Therapeutics Inc. (« FORUS »), a le plaisir d'annoncer que le 31 mai 2022, Santé Canada a autorisé la vente de XPOVIO® (selinexor) en association avec le bortézomib et la dexaméthasone pour le traitement des patients adultes...

(Saint-lgnace-de-Stanbridge, Quebec) May 28th, 2022 – FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome.  This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada...

(TORONTO, Ontario) May 2-3, 2022 ­– FORUS Therapeutics Inc, a Canadian Life Sciences company specialized in developing and commercializing unique and differentiated oncology focused therapies is proud to be participating and presenting at the 2022 Bloom Burton &...

(OAKVILLE, Ontario) February 22, 2022 ­– FORUS Therapeutics, a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer, today announced it has secured $2.5M CAD in growth capital...

FORUS Therapeutics a le plaisir d’annoncer la nomination de Marie-Josèphe Champagne au poste de liaison médicale scientifiques principale pour le Québec et l’Atlantique.  Marie-Josèphe a plus de 18 ans d’expérience dans l’industrie pharmaceutique dans des rôles...

Despite all the global and local challenges; related and unrelated to the pandemic, 2021 has been a year of tremendous growth, progress and development at FORUS. We are excited about 2022 and look forward to fulfilling our mission by bringing innovative new medicines...

In recognition of this last day of September and the close of Blood Cancer Awareness Month, FORUS Therapeutics Inc. is pleased to announce that Health Canada has accepted for review the New Drug Submission (NDS) for once-weekly XPOVIO® (selinexor) in combination with...

FORUS Therapeutics is excited to introduce Kim Newhouse as the Senior Medical Manager. Recognized as a dedicated medical affairs business partner with a drive to deliver with excellence, Kim brings two decades of hematology/oncology launch experience in the Canadian...

We are thrilled to introduce Tracy Nagy as the Senior Medical Science Liaison for Central Canada. Tracy has dedicated her over 35-year career to patients in hematology/oncology including extensive experience as a MSL and as a Nurse Practitioner/Transplant Coordinator...

FORUS Therapeutics is delighted to introduce Deirdre Hay as the Senior Medical Science Liaison for Western Canada. Deirdre has extensive experience in both commercial and medical affairs roles in hematology and oncology, with the last 10 years as a MSL focused on...

We are very pleased to announce that Alison Vanlerberghe has joined the FORUS Therapeutics team as our Market Access Lead. An industry recognized leader in Market Access, Alison brings a wealth of experience and partnership success, having formed multi-stakeholder...